Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial-Reference-Cited by-同舟云学术

Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial

Published:2004-10-18 Issue:11 Volume:34 Page:963-968
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Walsh T,Morris A K,Holle L M,Callander N,Bradshaw P,Valley A W,Clark G,Freytes C O

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1704714.pdf

Reference24 articles.

1. Hesketh PJ . Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163–173.

2. Navari R, Gandara D, Hesketh P et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242–1248.

3. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16: 1568–1573.

4. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 1994; 51: 113–118.

5. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group for Antiemetic Research. Ann Oncol 1995; 6: 805–810.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Antiemetic Prophylaxis with Fosaprepitant and 5-HT₃-Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

;Drug Design, Development and Therapy;2020-09

2. Transplant-Related Non-pain Issues: Prevention, Intervention, and Limitations;Supportive Care Strategies;2020

3. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy;Management of Chemotherapy-Induced Nausea and Vomiting;2016

4. Ondansetron and other 5HT3 receptor antagonists;Meyler's Side Effects of Drugs;2016

5. Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy;Future Oncology;2014-12